BiVISTA

This study is investigating whether a new vaccine, SII TCV(B), can protect against Salmonella Paratypi A infection, a bacteria that causes typhoid and paratyphoid fever (also called ‘Enteric fever’). The study will also evaluate whether the new vaccine is safe, well tolerated and how the immune response compares to an existing, licensed typhoid vaccine.

Enteric fever causes people to feel generally unwell, sometimes with high fevers, headache, muscle and joint aches, abdominal pain and constipation.  There are approximately 13 million cases of Enteric fever every year. Typhoid and paratyphoid fever are both spread via the faeces of an infected person, usually via contaminated water or food. It is usually found in parts of the world where people don’t have access to clean water and sanitation. In severe cases, or left untreated, it can cause death.

Results from this study may be used for licensing of the SII TCV(B) vaccine. 

This study is led by the Oxford Vaccine Group and is taking place at several sites across England. Research for the Future is currently supporting recruitment at the following sites: North Manchester General Hospital

• Age 18-55
• In good health
• Willing to travel to Liverpool or Oxford for one visit
• Smartphone and internet access required

• North Manchester General Hospital (M8 5RB)

• Vaccination with the study drug*
• Attending one clinic visit in Oxford or Liverpool (full day)
• Attending between 24-31 appointments over the 7 month study period (North Manchester General Hospital). These will include a range of tests including physical examinations, ultrasound and donating samples of blood, stool and saliva.
• Completing an electronic diary

*Participants will be randomly selected to receive either the new vaccine study drug or an existing typhoid vaccine.

Participants will receive reimbursement for their time, travel, inconvenience and overnight accommodation (if applicable).

Contact Us